Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
23 participants
OBSERVATIONAL
2009-12-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study hypothesis is: Fraction metabolized by CYP2C9 enzyme determines the extent of drug interactions in CYP2C9\*1/\*1 individuals but this factor (fraction metabolized) becomes less influential and drug interactions are attenuated in a gene-dose dependent manner in individuals with one or more defective alleles.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
NCT00964106
Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A
NCT03624959
Prediction of Drug Interactions With CYP2C9 Substrates
NCT00226538
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects
NCT02809768
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
NCT00860275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: Examine the extent of fluconazole inhibition of drugs with varying degrees of fraction metabolized by CYP2C9 in individuals with the CYP2C9\*1/\*1, CYP2C9\*1/\*3 and CYP2C9\*3/\*3 genotypes.
People differ in their genetic makeup. This includes differences in genes involved in drug metabolism, transport, and effect in the body. People with certain genetic profiles produce altered enzymes, transporters, and receptors that may respond in different ways to drugs. Altered enzymes cause some drugs to be broken down at a different rate than normal. As a result, drug concentrations build up in the blood, and increase the risk of side effects. Furthermore, when two drugs are taken together, the possibility exists for the drugs to interact, with one drug causing a change in the metabolism of the other or both of the drugs. It is not known whether people with an altered genetic makeup also have an altered experience with drug interactions. Altered drug transporters can affect the absorption and elimination of drugs as compared to normal causing differences in how long the drug stays in the body. Finally, altered drug receptors can respond differently to drugs and, thus, produce altered desired or undesired effects.
In this study, we will be investigating the drug interactions between an antifungal drug called fluconazole and the commonly used drugs tolbutamide, flurbiprofen, and ketoprofen in subjects with three different genotypes of the CYP2C9 enzyme. Tolbutamide is used for management of Type 2 diabetes. Both flurbiprofen and ketoprofen are non-steroidal anti-inflammatory drugs (NSAIDs) often used for arthritis or pain. We are interested in studying whether individuals with certain genetic profiles have different drug interactions than normal. This research is being done to see if certain genetic profiles require us to adjust medication doses differently than is needed for the general population.
The cytochrome P450 (CYP) superfamily of enzymes plays an important role in the oxidative conversion of numerous xenobiotics into their more hydrophilic metabolites. CYP2C9, is an important member of the CYP superfamily, accounting for 10-20% of the CYP protein content in human liver and catalyzes approximately 20% of the CYP mediated drug oxidation reactions, including tolbutamide and the non-steroidal anti-inflammatory drugs (NSAIDs) such as ketoprofen and flurbiprofen. It is now well established that genetic factors play an important role in the control of CYP2C9 expression and activity. In particular, the \*3 allele is expressed at an allele frequency of 15%. Homozygotic \*3 individuals exhibit significantly reduced oral clearance for several CYP2C9 substrates. In most of these cases, the reduction in clearance approaches 80% and even in heterozygotic individuals, this reduction in clearance is 40-50% due to the co-dominant expression of CYP2C9. This reduction in clearance has been associated with an increased frequency of adverse events following warfarin or phenytoin administration, two clinically important drugs that exhibit a narrow therapeutic index. The therapeutic index is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxic effects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CYP2C9*1/*1 Genotype
This genotype is considered the wild type genotype. Individuals with the CYP2C9\*1/\*1 genotype have two \*1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen \& Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen \& Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide \& Fluconazole.
Flurbiprofen Control - Flurbiprofen Only
A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Ketoprofen Control - Ketoprofen Only
A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Ketoprofen Inhibition - Ketoprofen & Fluconazole
A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Tolbutamide Control - Tolbutamide Only
A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
Tolbutamide Inhibition - Tolbutamide & Fluconazole
A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
CYP2C9*1/*3 Genotype
Individuals with the CYP2C9\*1/\*3 genotype have one \*1 allele and one \*3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen \& Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen \& Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide \& Fluconazole.
Flurbiprofen Control - Flurbiprofen Only
A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Ketoprofen Control - Ketoprofen Only
A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Ketoprofen Inhibition - Ketoprofen & Fluconazole
A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Tolbutamide Control - Tolbutamide Only
A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
Tolbutamide Inhibition - Tolbutamide & Fluconazole
A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
CYP2C9*3/*3 Genotype
Individuals with the CYP2C9\*3/\*3 genotype have two \*3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen \& Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen \& Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide \& Fluconazole.
Flurbiprofen Control - Flurbiprofen Only
A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Ketoprofen Control - Ketoprofen Only
A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Ketoprofen Inhibition - Ketoprofen & Fluconazole
A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Tolbutamide Control - Tolbutamide Only
A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
Tolbutamide Inhibition - Tolbutamide & Fluconazole
A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flurbiprofen Control - Flurbiprofen Only
A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Ketoprofen Control - Ketoprofen Only
A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Ketoprofen Inhibition - Ketoprofen & Fluconazole
A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Tolbutamide Control - Tolbutamide Only
A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
Tolbutamide Inhibition - Tolbutamide & Fluconazole
A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women of child-bearing age must be willing to use measures to avoid conception during the study period.
* Subjects must agree not to take any known substrates, inhibitors, inducers, or activators of CYP2C9.
Exclusion Criteria
* Abnormal renal or liver function tests, physical exam, or recent history of hepatic, renal, gastrointestinal or neoplastic disease.
* Allergy to tolbutamide, flurbiprofen, ketoprofen, fluconazole or phenytoin and other chemically related drugs.
* Recent ingestion (\< 1 week) of any medication known to be metabolized by or alter activity of CYP2C9.
* A positive pregnancy test during the time of the pharmacokinetic study.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of General Medical Sciences (NIGMS)
NIH
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Brundage, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical and Translational Science Institute
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0812M56082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.